Johns Hopkins ABX Guide
Rezafungin
INDICATIONS
FDA
FDA
- Treatment of candidemia or invasive candidiasis in patients 18 years of age and older who have limited to no treatment options
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Rezafungin is currently being investigated for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: November 13, 2023
Citation
Dzintars, Kathryn. "Rezafungin." Johns Hopkins ABX Guide, The Johns Hopkins University, 2023. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540786/9.0/Rezafungin.
Dzintars K. Rezafungin. Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540786/9.0/Rezafungin. Accessed April 28, 2024.
Dzintars, K. (2023). Rezafungin. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540786/9.0/Rezafungin
Dzintars K. Rezafungin [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. [cited 2024 April 28]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540786/9.0/Rezafungin.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Rezafungin
ID - 540786
A1 - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2023/11/13/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540786/9.0/Rezafungin
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
